Flyer - DVFA

th DVFA Life Science Conference
9
Next Level Targeted Therapies –
Game Changing Technologies for Future Medicine
14 June 2016
DVFA Center, Frankfurt am Main
Supported by
Schnee Research
Media Partner
Society of Investment Professionals in Germany
LIFE SCIENCE_
Conference
Invitation_
14 June 2016, 9 a.m.
The 9th DVFA-Life Science Conference focuses on the challenges and opportunities of Next Level Targeted Therapies in
Healthcare.
Targeted therapies have significantly changed the treatment environment for many life threatening diseases. The concepts are
as countless as diverse and cover small molecules, antibodies and cell therapies that fight cancer by interfering with specific carcinogenic pathways. The topic is highly relevant for big pharma, as collaborations between Roche and Kite Pharma and Celgene
and Juno show and, as a result, also for the capital markets. Declared as "Breakthrough of the Year 2015" by the prestigious
journal "Science", gene editing technology “CRISPR/Cas” becomes investable as impressively demonstrated by recent US-IPO of
Editas and the collaboration between Bayer and CRISPR Therapeutics. Discuss with industry and capital market experts innovative approaches such as gene editing, NGS, cancer vaccines, antibodies, CAR-T cell and gene therapy that have the potential
to revolutionize medicine.
u Topics

"Genome Editing – The Game Changer in Gene Therapy?!"

Decision making for targeted therapies in oncology enabled by molecular testing methods

New Opportunities with Advanced Viral Vector Technologies

Spiegelmer® Candidates in Clinical Development

Panel Discussion – How can current Game Changing Technologies be competitive?

Innovative Antibodies

CureVac – Revolutionizing Medical Treatment with Optimized mRNA

Directing the immune system to eliminate tumor cells

Dendritic Vaccines and T-Cell Therapy

Panel Discussion – Next Level Targeted Therapies from a Capital Markets Perspective
u Speakers & Moderators

Gbola Amusa, MD, CFA, Managing Director, Chardan Capital Markets, LLC

Dr. Christa Bähr, CEFA, CFA, Founder and Business Owner, CB HealthCare

Eric Blanchard, Partner, Covington & Burling LLP

Kai Brüning, CEFA, Senior Portfolio Manager, apoAsset Management GmbH

Prof. Dr. Boris Fehse, Professor for Cell and Gene Therapy, UMC Hamburg-Eppendorf

Ralf Frank, Secretary General, DVFA e.V.

Dr. Franz-Werner Haas, CCO, CureVac AG

Dr. Kai te Kaat, VP Head of Franchise Oncology, QIAGEN N.V.

Dr. Sven Klussmann, CSO and Founder, NOXXON Pharma AG

Dieter Lingelbach, COO, SIRION Biotech GmbH

Dr. med Markus Manns, Senior Equities Fund Manager, Union Investment Privatfonds GmbH

Nicholas Moore, Senior Vice President, Equity Capital Market, Jefferies International Ltd

Dr. Simon Moroney, CEO, MorphoSys AG

Karlheinz Schmelig, Creathor Venture Management GmbH

Dr. Christian Thirion, CEO/CTO, SIRION Biotech GmbH

Dr. Martin Treder, CSO, Affimed N.V.

Prof. Dr. Burghardt Wittig, Chairman, Foundation Institute Molecular Biology and Bioinformatics, FU Berlin

Dr. Olav Zilian, Senior Vice President Corporate Development, MediGene
u Target group
The conference is geared to company representatives, sector specialists, life science experts as well as practicians
and experts from research institutions.
u Participation
By invitation only. Participation is free of charge.
u Venue
DVFA Center, Mainzer Landstraße 37-39, 60329 Frankfurt am Main, Germany
Tel.: +49 (0) 69 24 24 94 08
LIFE SCIENCE
Programme
DVFA LIFE SCIENCE CONFERENCE_
14 June 2016
08:45 a.m. u
Check-in
09:00 a.m. u
Welcome
Dr. Christa Bähr, CEFA, CFA, Chairwoman DVFA Life Science Commission,
CB HealthCare
Ralf Frank, Secretary General, DVFA e.V.
09:10 a.m. u
"Genome Editing – The Game Changer in Gene Therapy?!"
Prof. Dr. Boris Fehse, Professor for Cell and Gene Therapy, UMC HamburgEppendorf
09:45 a.m. u
Decision Making for Targeted Therapies in Oncology Enabled by Molecular Testing Methods
Dr. Kai te Kaat, VP Head of Franchise Oncology, QIAGEN N.V.
10:20 a.m. u
New Opportunities with Advanced Viral Vector Technologies
Dr. Christian Thirion, CEO/CTO, SIRION Biotech GmbH
10:50 a.m. u
Coffee Break
11:10 a.m. u
Spiegelmer® Candidates in Clinical Development
Dr. Sven Klussmann, CSO and Founder, NOXXON Pharma AG
11:45 a.m. u
Panel I: How can Current Game Changing Technologies be Competitive?
• Gbola Amusa, MD, CFA, Managing Director, Chardan Capital Markets, LLC
• Dieter Lingelbach, COO, SIRION Biotech GmbH
• Dr. Martin Treder, CSO, Affimed N.V.
• Prof. Dr. Burghardt Wittig, Chairman, Foundation Institute Molecular
Biology and Bioinformatics, FU Berlin
• Moderation: Kai Brüning, CEFA, Senior Portfolio Manager,
apoAsset Management GmbH
12:45 p.m. u
Lunch
01:30 p.m. u
Innovative Antibodies
Dr. Simon Moroney, CEO, MorphoSys AG
02:05 p.m. u
CureVac – Revolutionizing Medical Treatment with Optimized mRNA
Dr. Franz-Werner Haas, CCO, CureVac AG
02:40 p.m. u
Directing the Immune System to Eliminate Tumor Cells
Dr. Martin Treder, CSO, Affimed N.V.
03:10 p.m. u
Coffee Break
03:30 p.m. u
Dendritic Vaccines and T-Cell Therapy
Dr. Olav Zilian, SVP Corporate Development, Medigene AG
04:05 p.m. u
Panel II: Next Level Targeted Therapies from a Capital Market Perspective
• Dr. Markus Manns, Union Investment Privatfonds GmbH
• Nicholas Moore, Senior Vice President, Equity Capital Market,
Jefferies International Ltd
• Karlheinz Schmelig, Creathor Venture Management GmbH
• Dr. Olav Zilian, SVP Corporate Development, Medigene AG
• Moderation: Eric Blanchard, Partner, Covington & Burling LLP
05:00 p.m. u
Get-together
Subject to modifications
Members of the DVFA Life Science Commission
Sascha Alilovic, MorphoSys AG, Martinsried/Planegg
Dr. Christa Bähr, CEFA, CFA, Chairwoman, CB HealthCare, Frankfurt
Dr. Viola Bronsema, BIO Deutschland e.V., Berlin
Kai Brüning, apo Asset Management GmbH, Düsseldorf
Ines-Regina Buth, CBA, akampion, Berlin
Dr. Ralf Emmerich, European Investment Fund, Luxemburg
Andreas Heinrichs, Bank Vontobel Europe AG, Köln
Stefan Höfer, Deutsche Börse AG, Eschborn
Dr. Kai Gregor Klinger, RHÖN-KLINIKUM AG, Bad Neustadt a.d. Saale
Dr. jur. Dr. med. Adem Koyuncu, COVINGTON & BURLING LLP, Brüssel
Dr. Solveigh Karola Mähler, MC SERVICES AG, Düsseldorf
Dr. med. Markus Manns, Chairman, Union Investment Privatfonds GmbH, Frankfurt
Dr. Markus Metzger, STADA Arzneimittel AG, Bad Vilbel
Dr. Marie-Luise Roth, DIB Deutsche Industrievereinigung Biotechnologie, Frankfurt
Dr. Martin Schnee, CBA, CCrA, Schnee Research, Maintal
Dr. Julia Schüler, CBA, BioMedServices, Darmstadt
Prof. Dr. Joerg Vienken, Nephro-Solutions AG, Hamburg
DVFA – Society of Investment Professionals in Germany
DVFA
Ulf Mayer
Tel.: +49 (0)69 264848 124
Fax: +49 (0)69 264848 489
Mail: [email protected]
Content: DVFA
Photos: www.shutterstock.com
DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently,
DVFA has more than 1,400 individual members representing over 400 investment firms,
banks, asset managers, consultants and counselling businesses. DVFA assures the
credibility of the professionals and the integrity of the market by offering internationally
recognised qualification programmes, by providing platforms for professional financial
communication, and by effective self-regulation.
Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access
to a pan-European network with more than 17,000 investment professionals in 27 nations. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is
part of a worldwide network of more than 100,000 investment professionals.
Subject to modifications. Copyright 2016 DVFA e.V.

Download Report